Problems in laboratory monitoring of heparin dosage

H. Croizat, L. Ponchio, F. E. Nicolini, R. L. Nagel, C. J. Eaves

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

1. The anticoagulant of choice for monitoring UFH therapy is CTAD (Van den Besselaar et al. 1987). 2. Samples should be collected 4-6 h after initiation on infusion, injection or dose adjustment (Olson et al, 1998). 3. When employing APTT for monitoring UFH, the responsiveness of the monitoring system must be taken into account when recommending a therapeutic range (Brill-Edwards et al, 1993; Kitchen & Preston, 1996), and should correspond to 0.2-0.4 units/ml by protamine titration or 0.35-0.7 units/ml by anti-Xa assay (Hirsh, 1991). 4. The heparin level can be used for monitoring UFH, particularly when APTT is inappropriate (Levine et al, 1994). 5. Clinically stable patients receiving LMWH as DVT prophylaxis or uncomplicated patients treated for venous thromboembolism by a weight-adjusted fixed dose, do not require laboratory monitoring (Laposata et al, 1998). 6. LMWH may require monitoring in selected cases such as renal insufficiency, prolonged therapy including pregnancy, paediatric patients, those at high risk of bleeding or thrombotic recurrence, and patients with obesity or low body-weight (Laposata et al, 1998). 7. A target therapeutic range of 0.5-1.1 iu/ml has been recommended for patients receiving twice daily LMWH therapy (Laposata et al, 1998). 8. Anti-Xa-activity assays for LMWH should be calibrated using a material itself calibrated against the International Standard for LMWH. 9. Results of anti-Xa assays may vary according to the technique employed (Kitchen et al, 1999b).

Original languageEnglish
Pages (from-to)397-406
Number of pages10
JournalBritish Journal of Haematology
Volume111
Issue number2
DOIs
Publication statusPublished - 2000

Fingerprint

Low Molecular Weight Heparin
Heparin
Therapeutics
Protamines
Venous Thromboembolism
Anticoagulants
Renal Insufficiency
Obesity
Body Weight
Pediatrics
Hemorrhage
Weights and Measures
Recurrence
Pregnancy
Injections

Keywords

  • Heparin
  • Laboratory monitoring
  • LMWH

ASJC Scopus subject areas

  • Hematology

Cite this

Croizat, H., Ponchio, L., Nicolini, F. E., Nagel, R. L., & Eaves, C. J. (2000). Problems in laboratory monitoring of heparin dosage. British Journal of Haematology, 111(2), 397-406. https://doi.org/10.1046/j.1365-2141.2000.02308.x

Problems in laboratory monitoring of heparin dosage. / Croizat, H.; Ponchio, L.; Nicolini, F. E.; Nagel, R. L.; Eaves, C. J.

In: British Journal of Haematology, Vol. 111, No. 2, 2000, p. 397-406.

Research output: Contribution to journalArticle

Croizat, H, Ponchio, L, Nicolini, FE, Nagel, RL & Eaves, CJ 2000, 'Problems in laboratory monitoring of heparin dosage', British Journal of Haematology, vol. 111, no. 2, pp. 397-406. https://doi.org/10.1046/j.1365-2141.2000.02308.x
Croizat, H. ; Ponchio, L. ; Nicolini, F. E. ; Nagel, R. L. ; Eaves, C. J. / Problems in laboratory monitoring of heparin dosage. In: British Journal of Haematology. 2000 ; Vol. 111, No. 2. pp. 397-406.
@article{6f491f8912234507a428db58579bd833,
title = "Problems in laboratory monitoring of heparin dosage",
abstract = "1. The anticoagulant of choice for monitoring UFH therapy is CTAD (Van den Besselaar et al. 1987). 2. Samples should be collected 4-6 h after initiation on infusion, injection or dose adjustment (Olson et al, 1998). 3. When employing APTT for monitoring UFH, the responsiveness of the monitoring system must be taken into account when recommending a therapeutic range (Brill-Edwards et al, 1993; Kitchen & Preston, 1996), and should correspond to 0.2-0.4 units/ml by protamine titration or 0.35-0.7 units/ml by anti-Xa assay (Hirsh, 1991). 4. The heparin level can be used for monitoring UFH, particularly when APTT is inappropriate (Levine et al, 1994). 5. Clinically stable patients receiving LMWH as DVT prophylaxis or uncomplicated patients treated for venous thromboembolism by a weight-adjusted fixed dose, do not require laboratory monitoring (Laposata et al, 1998). 6. LMWH may require monitoring in selected cases such as renal insufficiency, prolonged therapy including pregnancy, paediatric patients, those at high risk of bleeding or thrombotic recurrence, and patients with obesity or low body-weight (Laposata et al, 1998). 7. A target therapeutic range of 0.5-1.1 iu/ml has been recommended for patients receiving twice daily LMWH therapy (Laposata et al, 1998). 8. Anti-Xa-activity assays for LMWH should be calibrated using a material itself calibrated against the International Standard for LMWH. 9. Results of anti-Xa assays may vary according to the technique employed (Kitchen et al, 1999b).",
keywords = "Heparin, Laboratory monitoring, LMWH",
author = "H. Croizat and L. Ponchio and Nicolini, {F. E.} and Nagel, {R. L.} and Eaves, {C. J.}",
year = "2000",
doi = "10.1046/j.1365-2141.2000.02308.x",
language = "English",
volume = "111",
pages = "397--406",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "John Wiley & Sons, Ltd (10.1111)",
number = "2",

}

TY - JOUR

T1 - Problems in laboratory monitoring of heparin dosage

AU - Croizat, H.

AU - Ponchio, L.

AU - Nicolini, F. E.

AU - Nagel, R. L.

AU - Eaves, C. J.

PY - 2000

Y1 - 2000

N2 - 1. The anticoagulant of choice for monitoring UFH therapy is CTAD (Van den Besselaar et al. 1987). 2. Samples should be collected 4-6 h after initiation on infusion, injection or dose adjustment (Olson et al, 1998). 3. When employing APTT for monitoring UFH, the responsiveness of the monitoring system must be taken into account when recommending a therapeutic range (Brill-Edwards et al, 1993; Kitchen & Preston, 1996), and should correspond to 0.2-0.4 units/ml by protamine titration or 0.35-0.7 units/ml by anti-Xa assay (Hirsh, 1991). 4. The heparin level can be used for monitoring UFH, particularly when APTT is inappropriate (Levine et al, 1994). 5. Clinically stable patients receiving LMWH as DVT prophylaxis or uncomplicated patients treated for venous thromboembolism by a weight-adjusted fixed dose, do not require laboratory monitoring (Laposata et al, 1998). 6. LMWH may require monitoring in selected cases such as renal insufficiency, prolonged therapy including pregnancy, paediatric patients, those at high risk of bleeding or thrombotic recurrence, and patients with obesity or low body-weight (Laposata et al, 1998). 7. A target therapeutic range of 0.5-1.1 iu/ml has been recommended for patients receiving twice daily LMWH therapy (Laposata et al, 1998). 8. Anti-Xa-activity assays for LMWH should be calibrated using a material itself calibrated against the International Standard for LMWH. 9. Results of anti-Xa assays may vary according to the technique employed (Kitchen et al, 1999b).

AB - 1. The anticoagulant of choice for monitoring UFH therapy is CTAD (Van den Besselaar et al. 1987). 2. Samples should be collected 4-6 h after initiation on infusion, injection or dose adjustment (Olson et al, 1998). 3. When employing APTT for monitoring UFH, the responsiveness of the monitoring system must be taken into account when recommending a therapeutic range (Brill-Edwards et al, 1993; Kitchen & Preston, 1996), and should correspond to 0.2-0.4 units/ml by protamine titration or 0.35-0.7 units/ml by anti-Xa assay (Hirsh, 1991). 4. The heparin level can be used for monitoring UFH, particularly when APTT is inappropriate (Levine et al, 1994). 5. Clinically stable patients receiving LMWH as DVT prophylaxis or uncomplicated patients treated for venous thromboembolism by a weight-adjusted fixed dose, do not require laboratory monitoring (Laposata et al, 1998). 6. LMWH may require monitoring in selected cases such as renal insufficiency, prolonged therapy including pregnancy, paediatric patients, those at high risk of bleeding or thrombotic recurrence, and patients with obesity or low body-weight (Laposata et al, 1998). 7. A target therapeutic range of 0.5-1.1 iu/ml has been recommended for patients receiving twice daily LMWH therapy (Laposata et al, 1998). 8. Anti-Xa-activity assays for LMWH should be calibrated using a material itself calibrated against the International Standard for LMWH. 9. Results of anti-Xa assays may vary according to the technique employed (Kitchen et al, 1999b).

KW - Heparin

KW - Laboratory monitoring

KW - LMWH

UR - http://www.scopus.com/inward/record.url?scp=0034537596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034537596&partnerID=8YFLogxK

U2 - 10.1046/j.1365-2141.2000.02308.x

DO - 10.1046/j.1365-2141.2000.02308.x

M3 - Article

C2 - 11122078

AN - SCOPUS:0034537596

VL - 111

SP - 397

EP - 406

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -